<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of Raynaud phenomenon</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of Raynaud phenomenon</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of Raynaud phenomenon</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fredrick M Wigley, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Creager, MD, FAHA, FACC, MSVM</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits. The underlying problem is thought to be abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses.</p><p>RP is considered primary if these symptoms occur alone without evidence of any associated disorder. By comparison, secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc; scleroderma).</p><p>The clinical manifestations and diagnosis of RP are reviewed here. The pathogenesis and treatment of this disorder are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7553.html" rel="external">"Pathogenesis and pathophysiology of Raynaud phenomenon"</a> and  <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>.)</p><p class="headingAnchor" id="H303367046"><span class="h1">TERMINOLOGY</span></p><p class="headingAnchor" id="H25285296"><span class="h2">Primary versus secondary Raynaud phenomenon</span><span class="headingEndMark"> — </span>Patients with Raynaud phenomenon (RP) are described as having either a primary or secondary process.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary RP</strong> – Primary RP or idiopathic Raynaud disease are terms to describe manifestations in patients without evidence of any associated disorder as a cause for their vascular events. Most investigators feel the term "disease" is inappropriate and prefer using the term primary RP for otherwise healthy individuals. In this setting, RP is considered to be an exaggeration of normal vasoconstriction to cold exposure. (See  <a class="medical medical_review" href="/z/d/html/7553.html" rel="external">"Pathogenesis and pathophysiology of Raynaud phenomenon"</a>.)</p><p></p><p class="bulletIndent1">Primary RP usually has an age of onset between 15 and 30 years, is more common in females, and may occur in multiple related family members [<a href="#rid1">1</a>]. Although patients with primary RP are generally otherwise healthy, comorbid conditions can occur that may aggravate attacks. These include hypertension, atherosclerosis, cardiovascular disease, and diabetes mellitus. A meta-analysis of observational studies found that risk factors for primary RP included female sex, family history, smoking, manual occupation, migraine, and cardiovascular disease [<a href="#rid2">2</a>]. While nicotine exposure by smoking decreases cutaneous blood flow, the impact of chronic smoking on RP is not well defined [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1">There are conditions that appear to be associated with RP, but it is unclear if they are pathologically linked like the various causes of secondary RP. As an example, there is reportedly an increase in prevalence of RP among patients with fibromyalgia [<a href="#rid5">5,6</a>]. However, these reviews may have included subjects with secondary disease states. One study found that while patients with fibromyalgia have self-reported symptoms consistent with RP, direct testing found no association between skin temperature and digital color changes in patients with fibromyalgia, suggesting a different etiology than RP for skin changes in fibromyalgia [<a href="#rid5">5-9</a>].</p><p></p><p class="bulletIndent1">Similarly, there are several reviews that support an association of migraine headaches with RP [<a href="#rid10">10-13</a>]. It is not established that RP and migraine headache share a common cause or mechanism of vascular dysfunction. However, in spite of this, there remains an association of RP with migraine [<a href="#rid11">11,13-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary RP</strong> – Secondary RP manifests in patients who have an associated disease that may underlie the episodes. Some clinicians prefer the term Raynaud syndrome.</p><p></p><p class="bulletIndent1">A variety of mechanisms can disrupt the normal regulation of regional blood flow to the digits and skin, and thus, the number of diseases and exposures associated with secondary RP is extensive:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diseases commonly associated with RP include autoimmune rheumatic diseases such as systemic sclerosis (SSc; scleroderma), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren's syndrome, and dermatomyositis/polymyositis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Various drugs or toxins can also precipitate or exacerbate RP such as amphetamines and chemotherapeutic agents (especially <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic abnormalities associated with RP include cryoglobulinemia, cold agglutinin disease, paraproteinemia, POEMS (<strong>P</strong>olyneuropathy, <strong>O</strong>rganomegaly, <strong>E</strong>ndocrinopathy, <strong>M</strong>onoclonal protein, <strong>S</strong>kin changes) syndrome, and cryofibrinogenemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Occupational and environmental causes of RP include vascular trauma (eg, injury to the distal ulnar artery in hypothenar hammer syndrome) [<a href="#rid19">19-23</a>], the use of tools that vibrate [<a href="#rid24">24-27</a>], frostbite [<a href="#rid28">28</a>], and carpal tunnel syndrome [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypothyroidism may predispose to RP, and improvement of cold-induced vasospasm may occur with thyroid hormone replacement.</p><p></p><p class="bulletIndent1">It is important to distinguish occlusive vascular disease from the reversible events of RP. For example, inflammatory vascular disease or vasculitis may cause a blue cold finger and ischemic lesions due to irreversible loss of cutaneous blood flow. Diseases with occlusive vascular disease may also be associated with true RP. For example, RP is an early manifestation in up to 40 percent of patients with thromboangiitis obliterans (ie, Buerger's disease).</p><p></p><p class="bulletIndent1">Since primary RP is common in the general population, some of the reported associations of RP have remained unproven. As an example, the prevalence of RP in rheumatoid arthritis is controversial. Some surveys suggest no increase in risk [<a href="#rid30">30,31</a>], but other studies have found that 17 to 22 percent of patients with rheumatoid arthritis had RP [<a href="#rid32">32,33</a>]. Those with RP were more likely to have vasculitis or severe disease [<a href="#rid32">32,33</a>].</p><p></p><p class="headingAnchor" id="H536557134"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Establishing the true prevalence of Raynaud phenomenon (RP) is hampered by the lack of a well-defined reproducible "gold standard" diagnostic test. Cold hands and feet are a normal physiologic response to cold exposure that, to preserve heat, cools the surface skin and causes skin color changes, whereas RP is an exaggerated vascular response to cold temperature or emotional stress. Although survey criteria vary, most investigators agree that a history of at least two color changes (pallor and cyanosis) after cold exposure is necessary for a definite diagnosis.</p><p>Community-based surveys have been performed to estimate the prevalence of RP in the general population. In these surveys, estimates of the prevalence of RP have ranged from 3 to 20 percent in females and 3 to 14 percent in males.</p><p>These relatively wide ranges reflect, in part, the populations that are studied [<a href="#rid16">16,17,34-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>RP is more common in France (17 percent) than in the United States (5 percent) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A survey performed by the author in an African American community found a prevalence of 3 percent [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As reported in a community survey of 1525 participants, the prevalence of primary RP was approximately 11 and 9 percent in females and males, respectively [<a href="#rid39">39</a>].</p><p></p><p>RP is more common among young females, younger age groups, and related family members of patients with RP [<a href="#rid1">1,2,10,12</a>]. There are few studies of RP in children [<a href="#rid40">40-43</a>]. RP often starts early in life, but the prevalence then appears to remain relatively constant throughout life [<a href="#rid44">44</a>]. A review found a 0.1 to 1 percent prevalence of new-onset RP among individuals over the age of 60 years [<a href="#rid45">45</a>]. A survey reported that low body weight was associated with an increased risk of RP in males and females [<a href="#rid46">46</a>]. Additionally, the prevalence of RP found in a given population is influenced by the climate of the region studied [<a href="#rid47">47</a>].</p><p>The true prevalence of RP in children is challenging to define due to the lack of good definition of cases. It is estimated that approximately 70 percent of childhood-onset RP is primary RP, while secondary RP cases are often related to autoimmune disease [<a href="#rid48">48,49</a>].</p><p>The reported frequencies and rates of development of a disease or disorder to which RP is secondary among patients initially thought to have primary RP vary. A meta-analysis of 10 articles including approximately 640 patients diagnosed with primary RP found that 81 patients (13 percent) eventually developed an autoimmune rheumatic disease [<a href="#rid50">50</a>]. In a longitudinal study including 307 patients with RP, the annual incidence of transition from presumed primary RP to secondary RP was 1 percent [<a href="#rid51">51</a>]. Other large cohorts of patients with an initial presentation suggesting primary RP reported that between 16 and 37 percent transition to secondary RP during the follow-up period [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Both primary and secondary Raynaud phenomenon (RP) most often affect the digits (ie, fingers, toes) [<a href="#rid54">54-57</a>]. Cutaneous vasospasm is also common at other sites, including the skin of the ears, nose, face, knees, and nipples. (See  <a class="medical medical_review" href="/z/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Nipple vasoconstriction'</a>.)</p><p>A Raynaud attack typically begins in a single finger and then spreads to other digits symmetrically in both hands. The index, middle, and ring finger are the most frequently involved digits, while the thumb is often spared entirely (particularly in primary RP) [<a href="#rid58">58</a>]. Involvement of the thumb may indicate a secondary cause of RP [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1872184061"><span class="h2">Signs and symptoms of Raynaud phenomenon</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Digital color changes</strong> – With both primary and secondary RP, a typical episode is characterized by the sudden onset of cold fingers (or toes) in association with sharply demarcated color changes of skin pallor (white attack) due to constricted blood flow, followed by cyanotic skin (blue attack), which indicates tissue hypoxia (<a class="graphic graphic_picture graphicRef66438" href="/z/d/graphic/66438.html" rel="external">picture 1</a>). With rewarming, the ischemic phase (white or blue attack) usually lasts for 15 to 20 minutes. The skin subsequently blushes upon recovery, thereby resulting in the erythema of reperfusion. The presence of self-reported or witnessed blue and white color changes are generally required for establishing the diagnosis. In patients with highly pigmented skin, the cutaneous changes may be more visible on the palmar surface of the fingers. (See <a class="local">'Presumptive diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Cold-induced skin color changes reflect the reversible vasospastic aspects of RP. However, more persistent digital vascular compromise (eg, persistent cyanosis without blanching) secondary to the irreversible and often progressive obliterative microangiopathy also contributes to digital vascular symptoms in systemic sclerosis (SSc; scleroderma). Patients with RP associated with SSc can experience digital color changes that persist between isolated RP events [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Digital vasculopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms of digital ischemia</strong> – The symptoms of RP may include pain resulting from low blood flow or ischemia. Ischemia can be transient or prolonged, with complete recovery or with varying levels of tissue injury. Acute ischemia refers to sudden compromise of nutritional blood lasting a short period of time, whereas chronic ischemia refers to a prolonged compromise to nutritional flow. (See  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia", section on 'Acute ischemia'</a> and  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia", section on 'Chronic ischemia'</a>.)</p><p></p><p class="bulletIndent1">As an example, an episode of acute ischemia may be mild and associated with sensations of pins and needles, numbness and/or clumsiness of the fingers, and finger pain or aching. The signs of mild RP should be completely reversible on rewarming or reduction of stress. Less severe disease is most commonly observed in those with primary RP. More persistent symptoms of digital vascular compromise in SSc appear to be associated with longer disease duration and may reflect progression of the underlying obliterative microangiopathy.</p><p></p><p class="bulletIndent1">Mild to severe ischemia can be observed in patients with secondary RP. As an example, with severe RP secondary to SSc, tissue loss (ulceration or gangrene typically located on the tips of the fingers) may result from severely reduced digital perfusion. (See  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia", section on 'Chronic ischemia'</a> and  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Digital vasculopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Livedo reticularis</strong> – During a cold response, patients with RP may also exhibit livedo reticularis; this is a violaceous mottling or reticular pattern of the skin of the arms and legs, sometimes with regular unbroken circles [<a href="#rid61">61</a>]. This finding is benign and completely reversible with rewarming. (See  <a class="medical medical_review" href="/z/d/html/16556.html" rel="external">"Approach to the patient with retiform (angulated) purpura"</a>.)</p><p></p><p class="bulletIndent1">By comparison, nonreversible skin changes may be observed in patients with vasculitis, occlusive vascular disease (eg, due to atheroemboli or thrombosis), or antiphospholipid syndrome (APS). These cutaneous changes may also be associated with irregular broken circles. Due to these differences, some experts advocate use of the term "livedo racemosa" rather than "livedo reticularis" for these cutaneous findings in patients with inflammatory or thrombotic vascular disease [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Precipitating factors</span><span class="headingEndMark"> — </span>Patients with both primary and secondary RP note that exposure to cold temperature triggers RP. More importantly, the provocation occurs during relative shifts from warmer to cooler temperatures. As a result, mild cold exposures such as air conditioning or the cold of the refrigerated food section of the grocery store may cause an attack. Although attacks occur locally in the fingers, a general body chill will also trigger an episode, even if the hands or feet areas are kept warm.</p><p>An attack of RP may also occur after stimulation of the sympathetic nervous system (such as emotional stress, sudden startling). It is not uncommon for the clinician to witness a typical attack during the first encounter with a frightened or nervous patient.</p><p class="headingAnchor" id="H150103612"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H847445732"><span class="h2">Presumptive diagnosis</span><span class="headingEndMark"> — </span>There are no simple office tests or other standard diagnostic criteria that can be used to diagnose RP. The evaluation of RP is initiated by asking the patient the following questions:</p><p class="bulletIndent1"><span class="glyph">●</span>Are your fingers unusually sensitive to cold?</p><p class="bulletIndent1"><span class="glyph">●</span>Do your fingers change color when exposed to cold?</p><p class="bulletIndent1"><span class="glyph">●</span>If the fingers change color, do they turn white, blue/purple, or both?</p><p></p><p>The patient's response to these questions can help make a presumptive diagnosis of RP [<a href="#rid54">54,57</a>]. This simple approach (<a class="graphic graphic_algorithm graphicRef132060" href="/z/d/graphic/132060.html" rel="external">algorithm 1</a>) is generally consistent with various other proposed systems that generally rely on self-reporting and focus on an episodic paradigm of RP requiring cold sensitivity along with vasospastic events manifesting as digital color changes [<a href="#rid63">63-66</a>]. In addition to color changes, symptoms may include paresthesias and numbness with cold exposure. Attempts to induce an attack, such as with a cold-water challenge, are <strong>not</strong> recommended since the responses are inconsistent even in those with definite RP.</p><p>In addition to evaluating the patient for possible conditions associated with secondary RP, they should be evaluated for conditions that may appear like RP. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H25285628"><span class="h2">Further evaluation</span><span class="headingEndMark"> — </span>Although extensive special testing is not always necessary, every patient with a presumptive diagnosis of RP should be carefully evaluated to identify clinical symptoms or signs indicative of a secondary disorder. This is accomplished initially with a careful history and physical examination.</p><p>The history should include the age of onset of the skin color changes, the involved digits, degree of symmetry and severity of the attacks, and any history of digital tissue loss. The physical examination should identify areas of tissue loss (eg, ulceration, gangrene) typically affecting the fingers or toes. Other sites that may be affected by cutaneous vasospasm should also be examined closely, including the skin of the ears, nose, face, knees, and nipples. A complete physical exam should also include a thorough musculoskeletal and cardiopulmonary evaluation, as possible clues that any underlying systemic rheumatic disease may be present. Peripheral pulses should be assessed for evidence of proximal (large) vessel disease.</p><p>Patients should also be asked questions about symptoms that may be suggestive of a systemic rheumatic disease (eg, systemic sclerosis [SSc; scleroderma] or systemic lupus erythematosus [SLE]) such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever</p><p class="bulletIndent1"><span class="glyph">●</span>Arthralgia/arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Myalgias</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia, gastroesophageal reflux</p><p class="bulletIndent1"><span class="glyph">●</span>Skin thickening, sclerodactyly</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary abnormalities</p><p></p><p>Patients should also be asked about potential exposures or aggravating factors including:</p><p class="bulletIndent1"><span class="glyph">●</span>Occupational and environmental factors – The patient should be asked about exposure to polyvinyl chloride, occupational or recreational cold exposure (eg, history of frostbite), exposure to excessive vibration (eg, jack hammer operator), repetitive hand trauma (carpenter, blacksmith), and history of carpal tunnel syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications or toxins – The patient should be questioned about recreational and prescription drugs including chemotherapeutic agents (especially <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>) [<a href="#rid18">18</a>], interferon [<a href="#rid67">67</a>], estrogen, sympathomimetic agents, ergotamines, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, nicotine, and narcotics. There are case reports of aggravation of RP after use of calcitonin gene-related peptide (CGRP) antagonists used to treat migraine headaches [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H25285634"><span class="h3">Nailfold capillary microscopy</span><span class="headingEndMark"> — </span>Nailfold capillaroscopy is a common method to help distinguish patients with primary RP from those with secondary RP and is typically performed by a rheumatologist or dermatologist.</p><p>Nailfold capillary microscopy is accomplished by dropping oil on the periungual area and examining with an ophthalmoscope set at diopter 40 or with a dissecting microscope. A specialized handheld dermatoscope that magnifies a view of the area is also available. High-magnification nailfold videocapillaroscopy is used in some specialty centers [<a href="#rid69">69</a>]. Enlarged or distorted capillary loops and/or dropout or loss of loops suggest an underlying (or an increased likelihood of developing) systemic rheumatic disease [<a href="#rid50">50,70-73</a>]. If the enlargement is associated with loss of capillaries, then the patient is more likely to have or develop SSc (<a class="graphic graphic_picture graphicRef79285" href="/z/d/graphic/79285.html" rel="external">picture 2</a>) [<a href="#rid71">71,74-76</a>]. Abnormal nailfold capillaries also can be seen in nonrheumatic disorders associated with microvascular disease [<a href="#rid77">77</a>]. Standardization of the interpretation of nailfold capillaries microscopy enhances the ability to distinguish normal from abnormal capillaries, and the features of SSc from other diseases [<a href="#rid78">78</a>] (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H68975649"><span class="h3">Limited role of other tools</span><span class="headingEndMark"> — </span>Other techniques to assess the vascular responses in the digits and skin are also available, but they are typically used in specialty centers or for research purposes. These tools include thermography, angiography, laser Doppler imaging, and direct measures of skin temperature and local blood flow [<a href="#rid79">79,80</a>]. Nailfold capillaroscopy, thermal imaging, and laser Doppler imaging each independently provide good discrimination between healthy controls and primary RP [<a href="#rid81">81</a>]. The response of the digital systolic blood pressure to cooling is associated with the RP attack frequency and has been used in clinical trials as a measure of RP severity [<a href="#rid82">82,83</a>]. Blood perfusion measured by laser speckle contrast imaging can distinguish patients with RP from those without, but is not widely available [<a href="#rid84">84,85</a>]. These laboratory-based tools are useful for studying the physiology of RP but may not predict response to therapy or the severity of RP in an ambulatory setting.</p><p class="headingAnchor" id="H4183906993"><span class="h2">Diagnosing secondary versus primary Raynaud phenomenon</span><span class="headingEndMark"> — </span>Our approach to evaluating for secondary RP is summarized in an algorithm (<a class="graphic graphic_algorithm graphicRef132062" href="/z/d/graphic/132062.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary RP</strong> – We diagnose secondary RP if the results of a thorough history and physical examination, including nailfold capillary microscopy, suggest an underlying cause for RP.</p><p></p><p class="bulletIndent1">Other clinical features associated with a moderate or higher clinical suspicion of a secondary cause of RP include the following [<a href="#rid52">52,53,86-91</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Later age of onset (greater than 40 years)</p><p class="bulletIndent2"><span class="glyph">•</span>History of a known precipitant</p><p class="bulletIndent2"><span class="glyph">•</span>Male sex</p><p class="bulletIndent2"><span class="glyph">•</span>Painful severe events with tissue sign of ischemia (ulceration)</p><p class="bulletIndent2"><span class="glyph">•</span>Asymmetric attacks</p><p class="bulletIndent2"><span class="glyph">•</span>RP associated with signs or symptoms of another disease</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal nailfold capillaries</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal laboratory parameters suggesting vascular disease or an autoimmune disorder</p><p class="bulletIndent2"><span class="glyph">•</span>RP associated with ischemic signs or symptoms proximal to the fingers (such as the hand or arm) or toes (foot or limb)</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of autoantibodies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary RP</strong> – We diagnose primary RP in a patient if the history and physical examination does not suggest a secondary cause for RP, even if nailfold capillary microscopy cannot be performed. Clinical features associated with primary RP include the following [<a href="#rid63">63,92</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasospastic attack precipitated by cold or emotional stress</p><p class="bulletIndent2"><span class="glyph">•</span>Bilateral symmetric attacks</p><p class="bulletIndent2"><span class="glyph">•</span>No tissue necrosis or gangrene</p><p class="bulletIndent2"><span class="glyph">•</span>No history or physical findings suggestive of secondary cause of RP</p><p class="bulletIndent2"><span class="glyph">•</span>Normal nailfold capillaries</p><p class="bulletIndent2"><span class="glyph">•</span>Normal erythrocyte sedimentation rate (ESR)</p><p class="bulletIndent2"><span class="glyph">•</span>Absence of autoantibodies</p><p></p><p class="bulletIndent1">Nailfold capillary studies are ideal, but skills to do such an assessment may not be readily available to the primary care clinician. If other features point away from a secondary autoimmune disease, nailfold capillary assessment is not required. If felt to be necessary, referral for nailfold capillary microscopy (typically performed by a rheumatologist or dermatologist) would only be recommended if there is a clinical suspicion of a secondary RP or autoimmune disease.</p><p></p><p class="bulletIndent1">Among patients with probable primary RP, there is no need for further specialized laboratory testing. However, we recognize that serologic testing such as antinuclear antibody (ANA) is often done in this clinical setting. A weakly positive ANA (&lt;1/160) is common in the general population; therefore, a positive test must be interpreted in the context of the entire clinical situation. (See  <a class="medical medical_review" href="/z/d/html/1822.html" rel="external">"Measurement and clinical significance of antinuclear antibodies"</a>.)</p><p></p><p class="bulletIndent1">The key is careful serial follow-up of patients with probable primary RP to confirm the clinical diagnosis. Periodic follow-up is necessary to ensure that signs and/or symptoms of secondary causes of RP do not emerge. Most studies find that a transition to a defined secondary systemic rheumatic disease usually occurs within two to five years of presentation with RP; however, the interval may be more prolonged [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H3204814592"><span class="h3">Laboratory testing for secondary Raynaud phenomenon</span><span class="headingEndMark"> — </span>If the clinical evaluation defines features consistent with primary RP, then additional diagnostic testing specific for RP is generally not necessary. However, we monitor the patient annually (or sooner) for the development of signs and symptoms of diseases associated with secondary RP.</p><p>Patients with a suspicion of a diagnosis of secondary RP, with or without abnormal nailfold capillaries, should undergo additional testing. The exact laboratory tests should be guided by the clinical findings from the history and physical examination. (See <a class="local">'Further evaluation'</a> above.)</p><p>We generally obtain the following laboratory tests in most patients with newly diagnosed secondary RP:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and differential</p><p class="bulletIndent1"><span class="glyph">●</span>Complete metabolic panel</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis with urine sediment </p><p class="bulletIndent1"><span class="glyph">●</span>ANA (ideally by indirect immunofluorescence testing)</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone (TSH)</p><p class="bulletIndent1"><span class="glyph">●</span>ESR and/or C-reactive protein (CRP) levels</p><p></p><p>Additional laboratory tests may be warranted depending on the presence of other clinical symptoms. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with sclerodactyly and digital ulcers, antibodies specific for SSc such as antitopoisomerase I (anti-Scl-70), anticentromere, and anti-RNA polymerase III should be obtained. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patents with suspected inflammatory myopathy, creatinine kinase and possibly other myositis-specific autoantibodies (eg, anti-Jo-1) should be obtained. (See  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with suspected SLE or cryoglobulinemia, serum C3 and C4 complement levels should be obtained. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a suspected paraproteinemia, serum protein electrophoresis (SPEP) should be obtained.</p><p></p><p class="headingAnchor" id="H1835639263"><span class="h2">Vascular imaging for atypical attacks</span><span class="headingEndMark"> — </span>Patients who have a history of single-digit or asymmetric attacks, absent pulses, asymmetric blood pressure, or evidence of chronic ischemia should undergo vascular imaging to evaluate for conditions causing large vessel occlusive disease (eg, subclavian stenosis), medium vessel obstruction (eg, thromboembolic debris, medial calcification), or small vessel disease (eg, thromboangiitis obliterans). The selection of vascular imaging (eg, arterial duplex ultrasonography, computed tomographic [CT] or magnetic resonance [MR] angiography, or digital subtraction angiography) depends on the features of the clinical presentation. (See  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia", section on 'Vascular imaging'</a>.)</p><p class="headingAnchor" id="H25284919"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Conditions that can cause upper extremity, including hand, ischemia, are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia"</a>.)</p><p>There are several conditions and disorders that can mimic Raynaud phenomenon (RP):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excessive cold sensitivity</strong> – Many individuals report excessive cold sensitivity of cold hands and feet when they are exposed to a cold environment, but they do not see skin color changes. In one study, 10 percent of those surveyed had cold sensitivity [<a href="#rid93">93</a>]. This common complaint of cold hands and feet may be a familial trait [<a href="#rid94">94</a>]. Cold sensitivity and decreased skin blood flow following cold exposure occurs more commonly in females and in the older population [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>External compression of blood vessels</strong> – External compression of blood vessels (eg, carrying a heavy parcel) can cause a transient decrease in blood flow, and, as a consequence, a hand and fingers can be temporally numb, pale, and/or cold. Unlike RP, this is not induced by cold or stress and is easily reversed once blood flow is restored.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral neuropathy</strong> – Peripheral neuropathy can cause cold intolerance with numbness and skin color changes in the hands and feet [<a href="#rid96">96,97</a>]. However, unlike those with RP, patients with peripheral neuropathy may also have distal loss of sensation to pin prick, light touch, cold, and proprioception. (See  <a class="medical medical_review" href="/z/d/html/5278.html" rel="external">"Overview of lower extremity peripheral nerve syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/5282.html" rel="external">"Overview of upper extremity peripheral nerve syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complex regional pain syndrome</strong> – Complex regional pain syndrome (CRPS) is a disorder of a body region, usually the extremities, characterized by pain, paresthesia, vasomotor instability, and altered skin temperature [<a href="#rid98">98</a>]. Although patients with CRPS may have vasomotor disturbances that can produce altered color and temperature, this is typically followed by muscle wasting, which is not observed in primary RP, and the pain is usually continuous (in RP, pain is intermittent). (See  <a class="medical medical_review" href="/z/d/html/5628.html" rel="external">"Complex regional pain syndrome in adults: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occlusive vascular disease</strong> – Occlusive vascular disease (eg, emboli, thrombosis, atherosclerosis, thromboangiitis obliterans) can cause a cold limb, if acute occlusion occurs in a large vessel, or cause hand, foot, or digit ischemia, which may be associated with secondary vasospasm. Unlike typical RP, symptoms related to occlusive vascular disease are often asymmetric and when the hand is involved, are often limited to a single digit; vasospasm may be present with chronic ischemia but with complete vascular occlusion, may be irreversible and nonresponsive to vasodilator therapy. Vascular imaging will be needed to identify the occlusive lesion. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia"</a> and  <a class="medical medical_review" href="/z/d/html/14938.html" rel="external">"Embolism to the upper extremities"</a> and  <a class="medical medical_review" href="/z/d/html/112120.html" rel="external">"Embolism to the lower extremities"</a> and  <a class="medical medical_review" href="/z/d/html/8205.html" rel="external">"Thromboangiitis obliterans (Buerger disease)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acrocyanosis</strong> – Acrocyanosis is a functional peripheral vascular disorder characterized by symmetrical painless and persistent blue discoloration of the hands or feet, which is often aggravated by cold exposure [<a href="#rid99">99</a>]. Acrocyanosis can be differentiated from RP by the relative persistence of skin color changes, symmetry, and absence of paroxysmal pallor. As with RP, acrocyanosis is aggravated by cold exposure; however, it is also often associated with hyperhidrosis of hands and feet. RP attacks superimposed on acrocyanosis are not uncommon, and it may be difficult to distinguish the two disorders. Unlike RP, acrocyanosis rarely responds to vasodilator therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pernio (chilblains)</strong> – Pernio is an inflammatory cutaneous condition involving localized swelling and erythema caused by exposure to cold and damp conditions. Areas typically involved include the hands, feet, ears, and face. Unlike RP, in which the skin changes are transient, in patients with pernio there are papules, plaques, and nodular lesions. RP and acrocyanosis can also coexist with pernio. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute idiopathic blue finger</strong> – Acute idiopathic blue finger, also known as Achenbach syndrome or paroxysmal finger hematoma, is a rarely reported clinical disorder in which patients present with sudden onset of painful swelling of at least one digit, with an ecchymosis-like discoloration developing on the volar aspect of the finger [<a href="#rid100">100-103</a>]. The blue discoloration usually spares the distal segment of the finger. The clinical course is benign, and symptoms typically resolve without lasting sequelae.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythromelalgia</strong> – Erythromelalgia (EM) is an exaggerated blushing of the skin that can mimic the recovery phase or hyperemic phase of RP [<a href="#rid104">104</a>]. In contrast to RP, the vasodilatation associated with EM is triggered by warm temperature and is improved with cold exposure. In some cases, RP and EM may coexist [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/z/d/html/13766.html" rel="external">"Erythromelalgia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic acral vascular syndrome</strong> – Paraneoplastic acral vascular syndrome is a rare vascular disease associated with malignancy [<a href="#rid106">106</a>]. Patients present with manifestations of digital ischemia, including RP, acrocyanosis, and digital gangrene.</p><p></p><p class="headingAnchor" id="H119338791"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118057.html" rel="external">"Society guideline links: Raynaud phenomenon"</a>.) </p><p class="headingAnchor" id="H16"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15533.html" rel="external">"Patient education: Raynaud phenomenon (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3438.html" rel="external">"Patient education: Raynaud phenomenon (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Raynaud phenomenon</strong> – Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits (ie, fingers, toes). The underlying problem is thought to be abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses. RP is more common among young females, younger age groups, and related family members of patients with RP. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary versus secondary RP</strong> – Patients with RP are described as having either a primary or secondary process (see <a class="local">'Primary versus secondary Raynaud phenomenon'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary RP – Primary RP or idiopathic Raynaud disease are terms used to describe manifestations in patients without evidence of any associated disorder as a cause for their vascular events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary RP – Secondary RP manifests in patients who have an associated disease that may underlie the episodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms</strong> – With both primary and secondary RP, a typical episode is characterized by the sudden onset of cold fingers (or toes), often precipitated by exposure to cold surfaces or ambient temperature shifts. The episode occurs in association with sharply demarcated color changes of skin pallor (white attack) due to constricted blood flow, followed by cyanotic skin (blue attack), which indicates tissue hypoxia (<a class="graphic graphic_picture graphicRef66438" href="/z/d/graphic/66438.html" rel="external">picture 1</a>). With rewarming, the ischemic phase (white or blue attack) resolves. Ischemia can be transient, 15 to 20 minutes, or more prolonged. The skin subsequently blushes upon recovery, thereby resulting in the erythema of reperfusion. In patients with highly pigmented skin, the cutaneous changes may be more visible on the palmar surface of the fingers. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presumptive diagnosis</strong> – There are no simple office tests or other standard diagnostic criteria that can be used to diagnose RP. The evaluation of RP is initiated by asking the patient the following questions (see <a class="local">'Presumptive diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Are your fingers unusually sensitive to cold?</p><p class="bulletIndent2"><span class="glyph">•</span>Do your fingers change color when exposed to cold?</p><p class="bulletIndent2"><span class="glyph">•</span>If the fingers change color, do they turn white, blue/purple, or both?</p><p></p><p class="bulletIndent1">The patient's response to these questions help make a presumptive diagnosis of RP. Our diagnostic approach is summarized in an algorithm (<a class="graphic graphic_algorithm graphicRef132060" href="/z/d/graphic/132060.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Special testing is not always necessary, but every patient with a presumptive diagnosis of RP should be carefully evaluated to identify clinical symptoms or signs indicative of a secondary disorder, with a careful history and physical examination looking for clinical features suggestive of a systemic rheumatic disease (eg, systemic sclerosis [SSc; scleroderma] or systemic lupus erythematosus [SLE]) and to identify potential exposures or aggravating factors (eg, certain occupational and environmental factors, medications, and toxins). Patients with atypical attacks should undergo vascular imaging to evaluate for other conditions. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosing secondary versus primary RP</strong> – Our approach to evaluating for secondary RP is summarized in an algorithm (<a class="graphic graphic_algorithm graphicRef132062" href="/z/d/graphic/132062.html" rel="external">algorithm 2</a>). We diagnose secondary RP if the results of a thorough history and physical examination, including nailfold capillary microscopy, suggest underlying cause for RP. In the absence of an identified underlying cause, a diagnosis of primary RP can be made, even if nailfold capillary microscopy cannot be performed. However, for some patients, a secondary cause may manifest later on; these patients should be followed clinically. (See <a class="local">'Diagnosing secondary versus primary Raynaud phenomenon'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – There are several conditions and disorders that can mimic RP. These include excessive cold sensitivity, external compression of blood vessels, peripheral neuropathy, complex regional pain syndrome (CRPS), occlusive vascular disease, acrocyanosis, pernio (chilblains), acute idiopathic blue finger, erythromelalgia (EM), and paraneoplastic acral vascular syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39:1189.</a></li><li><a class="nounderline abstract_t">Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 2015; 5:e006389.</a></li><li><a class="nounderline abstract_t">Suter LG, Murabito JM, Felson DT, Fraenkel L. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am J Med 2007; 120:264.</a></li><li><a class="nounderline abstract_t">Prete M, Favoino E, Giacomelli R, et al. Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study. Clin Exp Med 2020; 20:31.</a></li><li><a class="nounderline abstract_t">Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 1986; 13:368.</a></li><li><a class="nounderline abstract_t">Bennett RM, Clark SR, Campbell SM, et al. Symptoms of Raynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielsen test, digital photoplethysmography, and measurements of platelet alpha 2-adrenergic receptors. Arthritis Rheum 1991; 34:264.</a></li><li><a class="nounderline abstract_t">Scolnik M, Vasta B, Hart DJ, et al. Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. Rheumatol Int 2016; 36:1371.</a></li><li><a class="nounderline abstract_t">Wolfe F, Petri M, Alarcón GS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009; 36:82.</a></li><li><a class="nounderline abstract_t">Vaerøy H, Helle R, Førre Ø, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32:21.</a></li><li><a class="nounderline abstract_t">de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988; 2:167.</a></li><li><a class="nounderline abstract_t">Zahavi I, Chagnac A, Hering R, et al. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med 1984; 144:742.</a></li><li><a class="nounderline abstract_t">Leppert J, Aberg H, Ringqvist I, Sörensson S. Raynaud's phenomenon in a female population: prevalence and association with other conditions. Angiology 1987; 38:871.</a></li><li><a class="nounderline abstract_t">O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Association between Raynaud's phenomenon and migraine in a random population of hospital employees. J Rheumatol 1993; 20:1187.</a></li><li><a class="nounderline abstract_t">O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. Ann Intern Med 1992; 116:985.</a></li><li><a class="nounderline abstract_t">Smyth AE, Hughes AE, Bruce IN, Bell AL. A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon. Rheumatology (Oxford) 1999; 38:1094.</a></li><li><a class="nounderline abstract_t">Voulgari PV, Alamanos Y, Papazisi D, et al. Prevalence of Raynaud's phenomenon in a healthy Greek population. Ann Rheum Dis 2000; 59:206.</a></li><li><a class="nounderline abstract_t">Cakir N, Pamuk ON, Dönmez S, et al. Prevalence of Raynaud's phenomenon in healthy Turkish medical students and hospital personnel. Rheumatol Int 2008; 29:185.</a></li><li><a class="nounderline abstract_t">Khouri C, Blaise S, Carpentier P, et al. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol 2016; 82:6.</a></li><li><a class="nounderline abstract_t">Spencer-Green G, Morgan GJ, Brown L, FitzGerald O. Hypothenar hammer syndrome: an occupational cause of Raynaud's phenomenon. J Rheumatol 1987; 14:1048.</a></li><li><a class="nounderline abstract_t">Yuen JC, Wright E, Johnson LA, Culp WC. Hypothenar hammer syndrome: an update with algorithms for diagnosis and treatment. Ann Plast Surg 2011; 67:429.</a></li><li><a class="nounderline abstract_t">Cooke RA. Hypothenar hammer syndrome: a discrete syndrome to be distinguished from hand-arm vibration syndrome. Occup Med (Lond) 2003; 53:320.</a></li><li><a class="nounderline abstract_t">Marie I, Hervé F, Primard E, et al. Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients. Medicine (Baltimore) 2007; 86:334.</a></li><li><a class="nounderline abstract_t">Swanson KE, Bartholomew JR, Paulson R. Hypothenar hammer syndrome: a case and brief review. Vasc Med 2012; 17:108.</a></li><li><a class="nounderline abstract_t">Noël B. Pathophysiology and classification of the vibration white finger. Int Arch Occup Environ Health 2000; 73:150.</a></li><li><a class="nounderline abstract_t">Heaver C, Goonetilleke KS, Ferguson H, Shiralkar S. Hand-arm vibration syndrome: a common occupational hazard in industrialized countries. J Hand Surg Eur Vol 2011; 36:354.</a></li><li><a class="nounderline abstract_t">Andréu JL, Otón T, Silva-Fernández L, Sanz J. Hand pain other than carpal tunnel syndrome (CTS): the role of occupational factors. Best Pract Res Clin Rheumatol 2011; 25:31.</a></li><li><a class="nounderline abstract_t">Roquelaure Y, Ha C, Le Manac'h AP, et al. Risk factors for Raynaud's phenomenon in the workforce. Arthritis Care Res (Hoboken) 2012; 64:898.</a></li><li><a class="nounderline abstract_t">Ervasti O, Hassi J, Rintamäki H, et al. Sequelae of moderate finger frostbite as assessed by subjective sensations, clinical signs, and thermophysiological responses. Int J Circumpolar Health 2000; 59:137.</a></li><li><a class="nounderline abstract_t">Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud's syndrome with carpal tunnel syndrome: a meta-analysis. Rheumatol Int 2012; 32:569.</a></li><li><a class="nounderline abstract_t">Carroll GJ, Withers K, Bayliss CE. The prevalence of Raynaud's syndrome in rheumatoid arthritis. Ann Rheum Dis 1981; 40:567.</a></li><li><a class="nounderline abstract_t">Grassi W, Blasetti P, Core P, Cervini C. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1994; 33:139.</a></li><li><a class="nounderline abstract_t">Saraux A, Allain J, Guedes C, et al. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1996; 35:752.</a></li><li><a class="nounderline abstract_t">Pope JE, Al-Bishri J, Al-Azem H, Ouimet JM. The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. J Rheumatol 2008; 35:2329.</a></li><li><a class="nounderline abstract_t">Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20:70.</a></li><li><a class="nounderline abstract_t">Harada N, Ueda A, Takegata S. Prevalence of Raynaud's phenomenon in Japanese males and females. J Clin Epidemiol 1991; 44:649.</a></li><li><a class="nounderline abstract_t">Purdie G, Harrison A, Purdie D. Prevalence of Raynaud's phenomenon in the adult New Zealand population. N Z Med J 2009; 122:55.</a></li><li><a class="nounderline abstract_t">Czirják L, Kiss CG, Lövei C, et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005; 23:801.</a></li><li><a class="nounderline abstract_t">Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol 1999; 52:441.</a></li><li><a class="nounderline abstract_t">Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005; 52:1259.</a></li><li><a class="nounderline abstract_t">Jones GT, Herrick AL, Woodham SE, et al. Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum 2003; 48:3518.</a></li><li><a class="nounderline abstract_t">Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003; 111:715.</a></li><li><a class="nounderline abstract_t">Rigante D, Fastiggi M, Ricci F, et al. Handy Hints About Raynaud's Phenomenon in Children: A Critical Review. Pediatr Dermatol 2017; 34:235.</a></li><li><a class="nounderline abstract_t">Pain CE, Constantin T, Toplak N, et al. Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clin Exp Rheumatol 2016; 34 Suppl 100:200.</a></li><li><a class="nounderline abstract_t">Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990; 301:590.</a></li><li><a class="nounderline abstract_t">Ling SM, Wigley FM. Raynaud's phenomenon in older adults: diagnostic considerations and management. Drugs Aging 1999; 15:183.</a></li><li><a class="nounderline abstract_t">Abdulle AE, Arends S, van Goor H, et al. Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women. Scand J Rheumatol 2021; 50:153.</a></li><li><a class="nounderline abstract_t">Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 1997; 24:879.</a></li><li><a class="nounderline abstract_t">Goldman RD. Raynaud phenomenon in children. Can Fam Physician 2019; 65:264.</a></li><li><a class="nounderline abstract_t">Turan E, Kilic SS. Retrospective view of primary Raynaud's phenomenon in childhood. Reumatol Clin (Engl Ed) 2019; 15:e92.</a></li><li><a class="nounderline abstract_t">Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158:595.</a></li><li><a class="nounderline abstract_t">Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54:1974.</a></li><li><a class="nounderline abstract_t">Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ, et al. Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients. Rheumatol Int 2013; 33:921.</a></li><li><a class="nounderline abstract_t">Bernero E, Sulli A, Ferrari G, et al. Prospective capillaroscopy-based study on transition from primary to secondary Raynaud's phenomenon: preliminary results. Reumatismo 2013; 65:186.</a></li><li><a class="nounderline abstract_t">Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.</a></li><li><a class="nounderline abstract_t">Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med 2016; 375:556.</a></li><li><a class="nounderline abstract_t">Hughes M, Herrick AL. Raynaud's phenomenon. Best Pract Res Clin Rheumatol 2016; 30:112.</a></li><li class="breakAll">Raynaud's Phenomenon: A Guide to Pathogenesis and Treatment, Wigley FM, Herrick AL, Flavahan NA (Eds), Springer, New York 2015.</li><li><a class="nounderline abstract_t">Chikura B, Moore TL, Manning JB, et al. Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford) 2008; 47:219.</a></li><li><a class="nounderline abstract_t">Chikura B, Moore T, Manning J, et al. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 2010; 37:783.</a></li><li><a class="nounderline abstract_t">Hughes M, Huang S, Pauling JD, et al. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. Clin Rheumatol 2022; 41:3049.</a></li><li><a class="nounderline abstract_t">Choi E, Henkin S. Raynaud's phenomenon and related vasospastic disorders. Vasc Med 2021; 26:56.</a></li><li><a class="nounderline abstract_t">Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol 2006; 33:2379.</a></li><li><a class="nounderline abstract_t">LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10:485.</a></li><li><a class="nounderline abstract_t">Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 1988; 15:454.</a></li><li><a class="nounderline abstract_t">Brennan P, Silman A, Black C, et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 1993; 32:357.</a></li><li><a class="nounderline abstract_t">Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun 2014; 48-49:60.</a></li><li><a class="nounderline abstract_t">Pitarokoili K, Kreuter A, Gold R, et al. Severe Raynaud’s phenomenon after treatment with interferon beta for multiple sclerosis. BMJ 2014; 349:g6166.</a></li><li><a class="nounderline abstract_t">Breen ID, Brumfiel CM, Patel MH, et al. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. JAMA Netw Open 2021; 4:e217934.</a></li><li><a class="nounderline abstract_t">Murray AK, Vail A, Moore TL, et al. The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc. Rheumatology (Oxford) 2012; 51:1323.</a></li><li><a class="nounderline abstract_t">Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16:75.</a></li><li><a class="nounderline abstract_t">Ingegnoli F, Boracchi P, Gualtierotti R, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum 2008; 58:2174.</a></li><li><a class="nounderline abstract_t">Lambova SN, Müller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 2009; 29:1263.</a></li><li><a class="nounderline abstract_t">Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008; 22:1093.</a></li><li><a class="nounderline abstract_t">ter Borg EJ, Piersma-Wichers G, Smit AJ, et al. Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 1994; 24:40.</a></li><li><a class="nounderline abstract_t">Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 2010; 62:2595.</a></li><li><a class="nounderline abstract_t">Anderson ME, Allen PD, Moore T, et al. Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. J Rheumatol 2005; 32:841.</a></li><li><a class="nounderline abstract_t">Mansueto N, Rotondo C, Corrado A, Cantatore FP. Nailfold capillaroscopy : a comprehensive review on common findings and clinical usefulness in non-rheumatic disease. J Med Invest 2021; 68:6.</a></li><li><a class="nounderline abstract_t">Smith V, Herrick AL, Ingegnoli F, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmun Rev 2020; 19:102458.</a></li><li><a class="nounderline abstract_t">Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008; 34:89.</a></li><li><a class="nounderline abstract_t">Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012; 8:469.</a></li><li><a class="nounderline abstract_t">Murray AK, Moore TL, Manning JB, et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009; 61:1103.</a></li><li><a class="nounderline abstract_t">Maricq HR, Jennings JR, Valter I, et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vasc Med 2000; 5:135.</a></li><li><a class="nounderline abstract_t">Nielsen SL. Raynaud phenomena and finger systolic pressure during cooling. Scand J Clin Lab Invest 1978; 38:765.</a></li><li><a class="nounderline abstract_t">Ruaro B, Smith V, Sulli A, et al. Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon. Front Pharmacol 2019; 10:360.</a></li><li><a class="nounderline abstract_t">Wilkinson JD, Leggett SA, Marjanovic EJ, et al. A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon. Arthritis Rheumatol 2018; 70:903.</a></li><li><a class="nounderline abstract_t">Landry GJ, Edwards JM, McLafferty RB, et al. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg 1996; 23:76.</a></li><li><a class="nounderline abstract_t">Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357:2042.</a></li><li><a class="nounderline abstract_t">Wollersheim H, Thien T, Hoet MH, Van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19:535.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.</a></li><li><a class="nounderline abstract_t">Weiner ES, Hildebrandt S, Senécal JL, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991; 34:68.</a></li><li><a class="nounderline abstract_t">Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58:3902.</a></li><li><a class="nounderline abstract_t">Allen EV, Brown GE. Raynaud's disease: A critical review of minimal requisites for diagnosis. Am J Med Sci 1932; 183:187.</a></li><li><a class="nounderline abstract_t">Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis 1986; 39:423.</a></li><li><a class="nounderline abstract_t">Hur YM, Chae JH, Chung KW, et al. Feeling of cold hands and feet is a highly heritable phenotype. Twin Res Hum Genet 2012; 15:166.</a></li><li><a class="nounderline abstract_t">Blatteis CM. Age-dependent changes in temperature regulation - a mini review. Gerontology 2012; 58:289.</a></li><li><a class="nounderline abstract_t">Irwin MS, Gilbert SE, Terenghi G, et al. Cold intolerance following peripheral nerve injury. Natural history and factors predicting severity of symptoms. J Hand Surg Br 1997; 22:308.</a></li><li><a class="nounderline abstract_t">Vinik AI, Erbas T, Stansberry KB, Pittenger GL. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2:S451.</a></li><li><a class="nounderline abstract_t">Wasner G. Vasomotor disturbances in complex regional pain syndrome--a review. Pain Med 2010; 11:1267.</a></li><li><a class="nounderline abstract_t">Kurklinsky AK, Miller VM, Rooke TW. Acrocyanosis: the Flying Dutchman. Vasc Med 2011; 16:288.</a></li><li><a class="nounderline abstract_t">Khaira HS, Rittoo D, Vohra RK, Smith SR. The non-ischaemic blue finger. Ann R Coll Surg Engl 2001; 83:154.</a></li><li><a class="nounderline abstract_t">Harper CM, Waters PM. Acute idiopathic blue finger: case report. J Hand Surg Am 2013; 38:1980.</a></li><li><a class="nounderline abstract_t">Carpentier PH, Maricq HR, Biro C, et al. Paroxysmal finger haematoma--a benign acrosyndrome occurring in middle-aged women. Vasa 2016; 45:57.</a></li><li><a class="nounderline abstract_t">Notomi K, Harada T. Achenbach syndrome. CMAJ 2019; 191:E584.</a></li><li><a class="nounderline abstract_t">Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000; 43:841.</a></li><li><a class="nounderline abstract_t">Chatterjee S. Coexistence of erythromelalgia and Raynaud's phenomenon. Joint Bone Spine 2023; 90:105561.</a></li><li><a class="nounderline abstract_t">Jud P, Raggam RB, Hafner F. Paraneoplastic acral vascular syndrome. CMAJ 2020; 192:E1470.</a></li></ol></div><div id="topicVersionRevision">Topic 7543 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8670329" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Familial aggregation of primary Raynaud's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25776043" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349450" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Smoking, alcohol consumption, and Raynaud's phenomenon in middle age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31679095" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487650" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848429" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Symptoms of Raynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielsen test, digital photoplethysmography, and measurements of platelet alpha 2-adrenergic receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27136918" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19004039" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2448729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410065" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An epidemiological survey of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6143540" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of Raynaud's phenomenon in patients with migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3425973" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Raynaud's phenomenon in a female population: prevalence and association with other conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371215" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Association between Raynaud's phenomenon and migraine in a random population of hospital employees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586109" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Increased prevalence of migraine and chest pain in patients with primary Raynaud disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556261" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700429" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of Raynaud's phenomenon in a healthy Greek population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682952" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of Raynaud's phenomenon in healthy Turkish medical students and hospital personnel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26949933" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Drug-induced Raynaud's phenomenon: beyondβ-adrenoceptor blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3430509" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypothenar hammer syndrome: an occupational cause of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372671" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypothenar hammer syndrome: an update with algorithms for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890831" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypothenar hammer syndrome: a discrete syndrome to be distinguished from hand-arm vibration syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18004178" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22169157" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypothenar hammer syndrome: a case and brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787129" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pathophysiology and classification of the vibration white finger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310765" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hand-arm vibration syndrome: a common occupational hazard in industrialized countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21663848" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hand pain other than carpal tunnel syndrome (CTS): the role of occupational factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22246858" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors for Raynaud's phenomenon in the workforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998831" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sequelae of moderate finger frostbite as assessed by subjective sensations, clinical signs, and thermophysiological responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21898061" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The association of Raynaud's syndrome with carpal tunnel syndrome: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7332376" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The prevalence of Raynaud's syndrome in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162478" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Raynaud's phenomenon in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8761187" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Raynaud's phenomenon in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843783" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441170" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066745" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevalence of Raynaud's phenomenon in Japanese males and females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145687" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of Raynaud's phenomenon in the adult New Zealand population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396698" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360339" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818710" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The incidence and natural history of Raynaud's phenomenon in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674003" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671102" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Raynaud's phenomenon in children: a retrospective review of 123 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28523890" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Handy Hints About Raynaud's Phenomenon in Children: A Critical Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27494080" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242457" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence of symptoms of Raynaud's phenomenon in general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10503811" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Raynaud's phenomenon in older adults: diagnostic considerations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33063580" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9150076" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30979757" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Raynaud phenomenon in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29426682" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Retrospective view of primary Raynaud's phenomenon in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521223" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22821334" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192563" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prospective capillaroscopy-based study on transition from primary to secondary Raynaud's phenomenon: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324557" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical practice. Raynaud's Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509103" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Raynaud's Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421220" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421220" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208825" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sparing of the thumb in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194444" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35583625" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33566754" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Raynaud's phenomenon and related vasospastic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143977" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1458701" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Raynaud's phenomenon: a proposal for classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3379622" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnosis of Raynaud's phenomenon assisted by color charts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495253" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491823" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : International consensus criteria for the diagnosis of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Severe Raynaud’s phenomenon after treatment with interferon beta for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33871613" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438458" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406812" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Microvasculature in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18576359" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19547979" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041079" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Capillaroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985036" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20506306" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15868619" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33994482" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Nailfold capillaroscopy : a comprehensive review on common findings and clinical usefulness in non-rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31927087" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18329535" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Diagnosis and management of scleroderma peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782008" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The pathogenesis, diagnosis and treatment of Raynaud phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644893" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11104295" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/741206" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Raynaud phenomena and finger systolic pressure during cooling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31073287" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29457381" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558745" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438158" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2515974" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261966" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845841" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035499" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Raynaud's disease: A critical review of minimal requisites for diagnosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711250" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22856358" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Feeling of cold hands and feet is a highly heritable phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085834" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Age-dependent changes in temperature regulation - a mini review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222907" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cold intolerance following peripheral nerve injury. Natural history and factors predicting severity of symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11460591" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Small fiber neuropathy and neurovascular disturbances in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20704675" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Vasomotor disturbances in complex regional pain syndrome--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427140" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Acrocyanosis: the Flying Dutchman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11432130" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The non-ischaemic blue finger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021741" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Acute idiopathic blue finger: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986711" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Paroxysmal finger haematoma--a benign acrosyndrome occurring in middle-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31133606" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Achenbach syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050591" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Erythromelalgia: new theories and new therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36933784" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Coexistence of erythromelalgia and Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33199454" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Paraneoplastic acral vascular syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
